9,640,000 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2023 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
286,000 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 6th, 2023 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
ROIVANT SCIENCES LTD. 26,666,666 Common Shares (par value $0.0000000341740141 per share) Underwriting AgreementUnderwriting Agreement • February 7th, 2023 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
Roivant Sciences Ltd., a Bermuda exempted limited company (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 26,666,666 of its common shares, par value $0.0000000341740141 per share (the “Shares”). The 26,666,666 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 3,999,999 Shares as provided in Section 2. The additional 3,999,999 Shares to be sold by the Company pursuant to such option are called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offer
3,770,000 Shares 3,770,000 Warrants to Purchase 3,770,000 Shares Avalo Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • February 3rd, 2023 • Avalo Therapeutics, Inc. • Pharmaceutical preparations • New York
6,620,000 Shares Pre-Funded Warrants to Purchase 2,905,000 Shares of Common Stock scPharmaceuticals Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • November 23rd, 2022 • scPharmaceuticals Inc. • Pharmaceutical preparations • New York
COGNITION THERAPEUTICS, INC. [_________] Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • November 7th, 2022 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Cognition Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of [_______] shares (the “Firm Shares”) of its common stock, par value $0.001 per share (“Common Stock”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional [_________] shares of Common Stock, which are collectively called the “Option Shares.” The Firm Shares and, if and to the extent such option is exercised, the Option Shares, are collectively called the “Offered Shares.” Cantor Fitzgerald & Co. (“Cantor”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean Cantor, as Underwriter, and the term “Underwriters” shall mean eith
13,333,333 Shares 13,333,333 Warrants to Purchase 13,333,333 Shares Codiak BioSciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • September 14th, 2022 • Codiak BioSciences, Inc. • Biological products, (no disgnostic substances) • New York
9,627,640 Shares of Common Stock 28,084 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • August 19th, 2022 • Viridian Therapeutics, Inc.\DE • Services-medical laboratories • New York
4,000,000 Shares TELA Bio, Inc. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 17th, 2022 • TELA Bio, Inc. • Surgical & medical instruments & apparatus • New York
Verona Pharma plc 12,400,000 American Depositary Shares Each Representing Eight Ordinary Shares (Nominal value £0.05 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2022 • Verona Pharma PLC • Pharmaceutical preparations • New York
7,868,854 Shares 327,868 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 23rd, 2022 • Xenon Pharmaceuticals Inc. • Pharmaceutical preparations • New York
25,464,483 Ordinary Shares Pre-Funded Warrants to Purchase 7,093,656 Ordinary Shares Wave Life Sciences Ltd. UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2022 • Wave Life Sciences Ltd. • Pharmaceutical preparations • New York
Arcellx, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2022 • Arcellx, Inc. • Biological products, (no disgnostic substances) • New York
10,000,000 Shares Concert Pharmaceuticals, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 3rd, 2022 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
HOLLEY INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 25th, 2022 • Holley Inc. • Motor vehicle parts & accessories • New York
9,803,922 Shares Liquidia Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • April 18th, 2022 • Liquidia Corp • Pharmaceutical preparations • New York
Introductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 9,803,922 shares of its common stock, par value $0.001 per share (the “Shares”). The 9,803,922 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,470,588 Shares as provided in Section 2. The additional 1,470,588 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” BofA Securities, Inc. (“BofA”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriter
Affimed N.V. 22,500,000 Common Shares (Par Value €0.01 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • April 18th, 2022 • Affimed N.V. • Pharmaceutical preparations • New York
TERAWULF INC. 2,985,966 Shares of Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • April 14th, 2022 • Terawulf Inc. • Services-computer processing & data preparation • New York
TeraWulf Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 2,985,966 shares of its common stock, par value $ 0.001 per share (the “Shares”). The 2,985,966 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 447,894.
8,695,653 Shares of Non-Voting Common Stock IGM Biosciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 30th, 2022 • IGM Biosciences, Inc. • Pharmaceutical preparations • New York
Number of Shares] Arcellx, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 31st, 2022 • Arcellx, Inc. • Biological products, (no disgnostic substances) • New York
AFC Gamma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • January 3rd, 2022 • AFC Gamma, Inc. • Real estate • New York
44,700,000 Shares of Common Stock and Warrants to Purchase 44,700,000 Shares of Common Stock Abeona Therapeutics Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 17th, 2021 • Abeona Therapeutics Inc. • Pharmaceutical preparations • New York
8,823,530 Shares RELMADA THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • December 13th, 2021 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • New York
Introductory. Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 8,823,530 shares of its common stock, par value $0.001 per share (the “Shares”). The 8,823,530 Shares to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 1,323,529 Shares as provided in Section 2. The additional 1,323,529 Shares to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Goldman Sachs & Co. LLC (“Goldman”), and Jefferies LLC (“Jefferies”) have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connection with the offering and sale of the Offered Shares. To t
6,250,000 Shares Adicet Bio, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 10th, 2021 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
As Representatives of the several Underwriters named in Schedule A attached hereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022
17,500,000 Shares of Common Stock MEI Pharma, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 6th, 2021 • MEI Pharma, Inc. • Pharmaceutical preparations • New York
3,448,275 Shares of Common Stock MIRATI THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2021 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • New York
Arteris, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2021 • Arteris, Inc. • Semiconductors & related devices • New York
•] Shares Ventyx Biosciences, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 15th, 2021 • Ventyx Biosciences, Inc. • Pharmaceutical preparations • New York
6,800,000 Firm Shares Sabra Health Care REIT, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 15th, 2021 • Sabra Health Care REIT, Inc. • Real estate investment trusts • New York
14,000,000 Ordinary Shares Warrants to Purchase 14,000,000 Ordinary Shares Osmotica Pharmaceuticals plc UNDERWRITING AGREEMENTUnderwriting Agreement • October 12th, 2021 • Osmotica Pharmaceuticals PLC • Pharmaceutical preparations • New York
774,194 Shares Cidara Therapeutics, Inc. Series X Preferred Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 8th, 2021 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
14,838,706 Shares Cidara Therapeutics, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 8th, 2021 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Manchester United plc 9,500,000 Class A Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 7th, 2021 • Manchester United PLC • Services-amusement & recreation services • New York
Introductory The shareholders of Manchester United plc, a Cayman Islands exempted company (the “Company”) named in Schedule A (collectively, the “Selling Shareholders”), propose to sell to the several underwriters named in Schedule B (the “Underwriters”) an aggregate of 9,500,000 Class A Ordinary Shares, par value $0.0005 per share (the “Shares”), of the Company. The 9,500,000 Shares to be sold by the Selling Shareholders are called the “Offered Shares.” BofA Securities, Inc. has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares.
8,474,577 Shares 1,694,915 Pre-funded Warrants Xenon Pharmaceuticals Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2021 • Xenon Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Number of Shares] THESEUS PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 30th, 2021 • Theseus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York